InflaRx's INF904 shows promise as immunomodulatory agent with biologic-like efficacy.

InflaRx's oral C5aR inhibitor INF904 has shown promising results in phase 2a trials for two conditions, HS and CSU. In HS, patients experienced significant reductions in abscesses, nodules, and draining tunnels, as well as improved pain scores. In CSU, patients showed substantial reductions in urticaria activity and improved disease control. These results suggest INF904 could be a best-in-class immunomodulatory agent. InflaRx plans to initiate phase 2b trials in 2026, focusing on HS.